LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cytokine Required by Immune Cells in Lungs to Defend Against Pneumonia Infection

By LabMedica International staff writers
Posted on 09 Aug 2016
Image: A photomicrograph of lung tissue infected by pneumonia bacteria (Photo courtesy of Alexandra Bettina, University of Virginia).
Image: A photomicrograph of lung tissue infected by pneumonia bacteria (Photo courtesy of Alexandra Bettina, University of Virginia).
The cytokine macrophage-colony stimulating factor (M-CSF) was been found to play a critical role in the ability of immune cells in the lung to defend against infection by pneumonia-causing bacteria.

M-CSF is a hematopoietic growth factor that is involved in the proliferation, differentiation, and survival of monocytes, macrophages, and bone marrow progenitor cells. M-CSF affects macrophages and monocytes in several ways, including stimulating increased phagocytic and chemotactic activity, and increased tumor cell cytotoxicity.

To develop a better understanding of how M-CSF functions in the lungs, investigators at the University of Virginia (Charlottesville, USA) tested the hypothesis that M-CSF was required for mononuclear phagocyte-mediated host defenses during bacterial pneumonia in a mouse model of pneumonia infection.

They reported in the June 15, 2016, issue of The Journal of Immunology that in the mouse model system genetic deletion or immuno-neutralization of M-CSF resulted in reduced survival, increased bacterial burden, and greater lung injury. M-CSF was necessary for the expansion of lung mononuclear phagocytes during infection but did not affect the number of bone marrow or blood monocytes, proliferation of precursors, or recruitment of leukocytes to the lungs. In contrast, M-CSF was essential to the animals' survival and to antimicrobial functions of both lung and liver mononuclear phagocytes during pneumonia. The absence of M-CSF resulted in bacterial dissemination to the liver and hepatic necrosis.

"If you take M-CSF away, the infections get worse, so that raises two important questions about therapy: Would more be better? It may be that during infection, the body is making the right amount of M-CSF and if we add extra, it will not improve outcomes further," said senior author Dr. Borna Mehrad, associate professor of internal medicine and microbiology at the University of Virginia. "The second possibility is that there is room for improvement: in the fight between monocytes and the bacteria, M-CSF may make monocytes live longer and give them an edge. In addition, some people with weakened immunity might not make enough of M-CSF. If that is the case, you could augment that and improve their ability to fight the infection."

"We are interested in seeing if there are things we can do to strengthen the natural defenses of the host to help them fight the infection more effectively," said Dr. Mehrad. "Potentially this would be the sort of thing you could do in addition to antibiotics to help patients with severe infections."

Related Links:
University of Virginia


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Pipette
Accumax Smart Series

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more